Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The primary objective of this study was to evaluate the efficacy of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD)-related symptoms assessed as standard variables of a computer-based continuous performance test (cb-CPT) combined with a motion-tracking (MT) device. This was a 2-arm, 8-week, randomized, double-blind, placebo-controlled study in patients with ADHD (6-12 years). Therapy with ATX started with 0.5 mg/kg per day for 1 week, followed by 7 weeks on the target dosage of 1.2 mg/kg per day. Primary outcomes were cb-CPT/MT standard scores after 8 weeks using mixed models for repeated measurements. In addition, investigator-rated ADHD Rating Scale (ADHD-RS), Weekly Ratings of Evening and Morning Behavior (WREMB), and Clinical Global Impression - Severity-ADHD (CGI-S-ADHD) scores were assessed. Of 128 patients randomized, 125 were evaluated (ATX/placebo: 63/62). Baseline characteristics were comparable in both groups (overall, 80.2% boys; mean [SD] age, 9.0 [1.79] years; comorbid Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis, 40.0% oppositional defiant disorder/conduct disorder; prior stimulant treatment, 24.8%; ADHD-RS total score, 36.99 [11.56]). At week 8, all cb-CPT/MT q-scores were significantly reduced versus placebo (all P < 0.001) with effect sizes (ESs) of reaction time (RT) variation (ES = 0.71), mean RT (ES = 0.41), number of microevents (ES = 1.00), commission error rate (ES = 0.50), distance of movement (ES = 0.90), area of movement (ES = 1.08), omission error rate (ES = 0.70), time active (ES = 0.69), motion simplicity (ES = 0.38), and normalized variance of RT (ES = 0.50). Secondary end points also improved significantly in favor of ATX: ADHD-RS (total score ES = 1.30, P < 0.001; hyperactivity/impulsivity subscore ES = 1.37, P < 0.001; inattention subscore ES = 1.07, P < 0.001), WREMB (total score ES = 1.00, P < 0.001; morning subscore ES = 0.59, P = 0.002; evening subscore ES = 1.02, P < 0.001), CGI-S-ADHD (ES = 1.11, P < 0.001). The results of this study show that ATX for 8 weeks significantly reduced ADHD-related symptoms as measured by the cb-CPT/MT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubia, K., Overmeyer, S., Taylor, E., Brammer, M., Williams, S. C. R., Simmons, A., & Bullmore, E. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.891 · Cited by 1,010
Varieties of Attention-Deficit/Hyperactivity Disorder-Related Intra-Individual Variability
Castellanos, F. X., Sonuga-Barke, E. J. S., Scheres, A., Di Martino, A., Hyde, C., & Walters, J. R. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.005 · Cited by 540 · cited 1×
“High-performance variability reflects symptoms such as difficulty in sustaining attention, forgetfulness, disorganization, and careless errors.(27) & Normalized variation of RT (nVRT) is RTV expressed as the standard deviation (SD) in units of mRT (RTV/mRT).”
BackgroundThe ecological validity of laboratory and analogue assessment methods of ADHD symptoms
Barkley, R. A. (1991) · Journal of Abnormal Child Psychology · doi:10.1007/bf00909976 · Cited by 419 · cited 1×
“Increased OE is related to selective attention and deficient arousal.(29)”
BackgroundObjective measurement of hyperactivity and attentional problems in ADHD
TEICHER, M. H., ITO, Y., GLOD, C. A., & BARBER, N. I. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199603000-00015 · Cited by 243
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185
Assessing medication effects in the MTA study using neuropsychological outcomes
Epstein, J. N., Keith Conners, C., Hervey, A. S., Tonev, S. T., Eugene Arnold, L., Abikoff, H. B., Elliott, G., Greenhill, L. L., Hechtman, L., Hoagwood, K., et al. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2005.01469.x · Cited by 139
Brocki, K. C., Tillman, C. M., & Bohlin, G. (2010) · European Journal of Developmental Psychology · doi:10.1080/17405620801937764 · Cited by 53 · cited 1×
“This method (referred to as ‘‘cb-CPT/MT’’) was developed on the basis of earlier approaches to measuring ADHD core symptoms, assessing attention, impulsivity, and hyperactivity quantitatively and has been found to reflect ADHD symptoms.(22,23) For the test, the patientwas seated in front of a screen,wearing a head ref…”
Method
Cited by
Soff, C., Sotnikova, A., Christiansen, H., Becker, K., & Siniatchkin, M. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-016-1646-y · Cited by 111
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“when ADHD-related symptoms were measured using a computer-based continuous performance test combined with a motion-tracking device [81].”
MethodStevenson, J., Buitelaar, J., Cortese, S., Ferrin, M., Konofal, E., Lecendreux, M., Simonoff, E., Wong, I. C. K., & Sonuga‐Barke, E. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12215 · Cited by 106
Kowalczyk, O. S., Cubillo, A. I., Smith, A., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., & Rubia, K. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.139 · Cited by 63
Joseph, A., Ayyagari, R., Xie, M., Cai, S., Xie, J., Huss, M., & Sikirica, V. (2017) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-017-0962-6 · Cited by 38
“Trials: Biederman [28]; Biederman [29]; Block [32]; Coghill [33]; Dittmann [34]; Dittmann [35]; Findling [36]; Findling [37]; Garg [38]; Gau [39]; Hervas [41]; Kelsey [42]; Kollins [43]; López [44]; Martenyi [45]; Montoya [48]; Newcorn [49]; Newcorn [50]; Palumbo [51]; Sallee [30]; Shang [52]; Spencer [31]; Steele [53…”
Background
Metadata
- Authors
- Wehmeier, P. M., Schacht, A., Ulberstad, F., Lehmann, M., Schneider-Fresenius, C., Lehmkuhl, G., Dittmann, R. W., & Banaschewski, T.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2012-10
- Volume
- 32
- Issue
- 5
- Pages
- 653-660
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2050261033
- Cited by
- 30
- References
- 7
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology. https://app.cochat.ai/papers/10.1097/jcp.0b013e318267c304
- The paper
- Wehmeier, P. M., Schacht, A., Ulberstad, F., Lehmann, M., Schneider-Fresenius, C., Lehmkuhl, G., Dittmann, R. W., & Banaschewski, T. (2012). Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318267c304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.